{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,17]],"date-time":"2026-07-17T08:08:28Z","timestamp":1784275708717,"version":"3.55.0"},"reference-count":187,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,7,17]],"date-time":"2026-07-17T00:00:00Z","timestamp":1784246400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2026,7,17]],"date-time":"2026-07-17T00:00:00Z","timestamp":1784246400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Immunol Res"],"DOI":"10.1007\/s12026-026-09808-9","type":"journal-article","created":{"date-parts":[[2026,7,17]],"date-time":"2026-07-17T06:24:02Z","timestamp":1784269442000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Decoding the PI3K\/Akt\/mTOR\u2013JAK\/STAT signaling axis in multiple sclerosis: mechanistic crosstalk and therapeutic opportunities"],"prefix":"10.1007","volume":"74","author":[{"given":"Chandrayee","family":"Banerjee","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rohit Kumar","family":"Singh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Divya","family":"Choudhary","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"MD Nasiruddin","family":"Khan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pankaj Kumar","family":"Maurya","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zuber","family":"Khan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0034-835X","authenticated-orcid":false,"given":"Sidharth","family":"Mehan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rajaram","family":"Samant","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Manoj","family":"Tongra","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,7,17]]},"reference":[{"issue":"4","key":"9808_CR1","doi-asserted-by":"publisher","first-page":"100139","DOI":"10.1016\/j.phyplu.2021.100139","volume":"1","author":"A Singh","year":"2021","unstructured":"Singh A, Upadhayay S, Mehan S. Inhibition of c-JNK\/p38MAPK signaling pathway by Apigenin prevents neurobehavioral and neurochemical defects in ethidium bromide-induced experimental model of multiple sclerosis in rats: Evidence from CSF, blood plasma and brain samples. Phytomedicine Plus. 2021;1(4):100139. https:\/\/doi.org\/10.1016\/j.phyplu.2021.100139.","journal-title":"Phytomedicine Plus"},{"key":"9808_CR2","doi-asserted-by":"publisher","DOI":"10.3390\/genes13081324","author":"S Upadhayay","year":"2022","unstructured":"Upadhayay S, Mehan S, Prajapati A, Sethi P, Suri M, Zawawi A, et al. Nrf2\/HO-1 signaling stimulation through acetyl-11-keto-beta-boswellic acid (AKBA) provides neuroprotection in ethidium bromide-induced experimental model of multiple sclerosis. Genes. 2022. https:\/\/doi.org\/10.3390\/genes13081324.","journal-title":"Genes"},{"issue":"2","key":"9808_CR3","doi-asserted-by":"publisher","first-page":"183","DOI":"10.1016\/S1474-4422(14)70256-X","volume":"14","author":"DH Mahad","year":"2015","unstructured":"Mahad DH, Trapp BD, Lassmann H. Pathological mechanisms in progressive multiple sclerosis. Lancet Neurol. 2015;14(2):183\u201393. https:\/\/doi.org\/10.1016\/S1474-4422(14)70256-X.","journal-title":"Lancet Neurol"},{"issue":"February","key":"9808_CR4","doi-asserted-by":"publisher","DOI":"10.1016\/j.jneumeth.2025.110415","volume":"418","author":"A Sharma","year":"2025","unstructured":"Sharma A, Sharma N, Khanna K, Arora A, Mehan S, Sharma A. Enhancing therapeutic efficacy of fingolimod via intranasal delivery in an ethidium bromide-induced model of multiple sclerosis. J Neurosci Methods. 2025;418(February):110415. https:\/\/doi.org\/10.1016\/j.jneumeth.2025.110415.","journal-title":"J Neurosci Methods"},{"issue":"6","key":"9808_CR5","doi-asserted-by":"publisher","first-page":"1556","DOI":"10.1007\/s11064-023-04082-9","volume":"49","author":"A Prajapati","year":"2024","unstructured":"Prajapati A, Mehan S, Khan Z, Chhabra S, Das Gupta G. Purmorphamine, a Smo-Shh\/Gli activator, promotes sonic hedgehog-mediated neurogenesis and restores behavioural and neurochemical deficits in experimental model of multiple sclerosis. Neurochem Res. 2024;49(6):1556\u201376. https:\/\/doi.org\/10.1007\/s11064-023-04082-9.","journal-title":"Neurochem Res"},{"key":"9808_CR6","doi-asserted-by":"publisher","DOI":"10.3390\/jcm12134274","author":"Z Khan","year":"2023","unstructured":"Khan Z, Gupta GD, Mehan S. Cellular and molecular evidence of multiple sclerosis diagnosis and treatment challenges. J Clin Med. 2023. https:\/\/doi.org\/10.3390\/jcm12134274.","journal-title":"J Clin Med"},{"issue":"18","key":"9808_CR7","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/S0140-6736(18)30481-1","volume":"6736","author":"AJ Thompson","year":"2018","unstructured":"Thompson AJ, Baranzini SE, Geurts J, Hemmer B, Ciccarelli O. Seminar Multiple sclerosis. Lancet [Internet]. 2018;6736(18):1\u201315. https:\/\/doi.org\/10.1016\/S0140-6736(18)30481-1.","journal-title":"Lancet [Internet]"},{"key":"9808_CR8","doi-asserted-by":"publisher","unstructured":"Shi M, Liu Y, Gong Q, Xu XMultiple sclerosis: an overview of epidemiology, risk factors, and serological biomarkers. Acta Neurol Scand. 2024;2024. https:\/\/doi.org\/10.1155\/2024\/7372789.","DOI":"10.1155\/2024\/7372789"},{"issue":"February","key":"9808_CR9","doi-asserted-by":"publisher","first-page":"104696","DOI":"10.1016\/j.msard.2023.104696","volume":"73","author":"H Houzen","year":"2023","unstructured":"Houzen H, Kano T, Kondo K, Takahashi T, Niino M. The prevalence and incidence of multiple sclerosis over the past 20 years in northern Japan. Mult Scler Relat Disord. 2023;73(February):104696. https:\/\/doi.org\/10.1016\/j.msard.2023.104696.","journal-title":"Mult Scler Relat Disord"},{"key":"9808_CR10","doi-asserted-by":"publisher","DOI":"10.1007\/s10072-022-06126-4","author":"D Jia","year":"2022","unstructured":"Jia D, Zhang Y, Yang C. The incidence and prevalence, diagnosis, and treatment of multiple sclerosis in China: a narrative review. Neurol Sci. 2022. https:\/\/doi.org\/10.1007\/s10072-022-06126-4.","journal-title":"Neurol Sci"},{"issue":"5","key":"9808_CR11","doi-asserted-by":"publisher","first-page":"1636","DOI":"10.1111\/ene.14764","volume":"28","author":"L Xu","year":"2021","unstructured":"Xu L, Chen L, Wang S, et al Urban prevalence of multiple sclerosis in China: A population-based study in six provinces. Eur J Neurol. 2021;28(5):1636\u201344. https:\/\/doi.org\/10.1111\/ene.14764.","journal-title":"Eur J Neurol"},{"key":"9808_CR12","doi-asserted-by":"publisher","first-page":"205521731666640","DOI":"10.1177\/2055217316666407","volume":"2","author":"E Correa","year":"2016","unstructured":"Correa E, Paredes V, Mart\u00ednez B Prevalence of multiple sclerosis in Latin America and its relationship with European migration. Mult Scler J Exp Transl Clin. 2016;2:2055217316666407. https:\/\/doi.org\/10.1177\/2055217316666407. Published 2016 Sep 2.","journal-title":"Mult Scler J Exp Transl Clin"},{"issue":"7","key":"9808_CR13","doi-asserted-by":"publisher","first-page":"844","DOI":"10.1177\/1352458512462918","volume":"19","author":"E Cristiano","year":"2013","unstructured":"Cristiano E, Rojas J, Romano M, et al The epidemiology of multiple sclerosis in Latin America and the Caribbean: a systematic review. Mult Scler. 2013;19(7):844\u201354. https:\/\/doi.org\/10.1177\/1352458512462918.","journal-title":"Mult Scler"},{"issue":"1","key":"9808_CR14","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1007\/s44197-025-00353-6","volume":"15","author":"G Khan","year":"2025","unstructured":"Khan G, Hashim MJ. Epidemiology of Multiple Sclerosis: Global, Regional, National and Sub-National-Level Estimates and Future Projections. J Epidemiol Glob Health. 2025;15(1):1\u201311.","journal-title":"J Epidemiol Glob Health"},{"issue":"14","key":"9808_CR15","doi-asserted-by":"publisher","first-page":"1816","DOI":"10.1177\/1352458520970841","volume":"26","author":"C Walton","year":"2020","unstructured":"Walton C, King R, Rechtman L, et al Rising prevalence of multiple sclerosis worldwide: Insights from the Atlas of MS, third edition. Mult Scler. 2020;26(14):1816\u201321. https:\/\/doi.org\/10.1177\/1352458520970841.","journal-title":"Mult Scler"},{"issue":"Suppl 1","key":"9808_CR16","doi-asserted-by":"publisher","first-page":"S2","DOI":"10.4103\/0972-2327.164812","volume":"18","author":"BS Singhal","year":"2015","unstructured":"Singhal BS, Advani H Multiple sclerosis in India: An overview. Ann Indian Acad Neurol. 2015;18(Suppl 1):S2\u20135. https:\/\/doi.org\/10.4103\/0972-2327.164812.","journal-title":"Ann Indian Acad Neurol"},{"issue":"2","key":"9808_CR17","doi-asserted-by":"publisher","first-page":"e105","DOI":"10.1016\/S2468-2667(21)00249-8","volume":"7","author":"E Nichols","year":"2022","unstructured":"Nichols E, Steinmetz JD, Vollset SE, Fukutaki K, Chalek J, Abd-Allah F, et al. Estimation of the global prevalence of dementia in 2019 and forecasted prevalence in 2050: an analysis for the Global Burden of Disease Study 2019. Lancet Public Heal. 2022;7(2):e105\u201325.","journal-title":"Lancet Public Heal"},{"issue":"5","key":"9808_CR18","doi-asserted-by":"publisher","first-page":"459","DOI":"10.1016\/S1474-4422(18)30499-X","volume":"18","author":"GBD 2016 Neurology Collaborators","year":"2019","unstructured":"GBD 2016 Neurology Collaborators Global, regional, and national burden of neurological disorders, 1990-2016: a systematic analysis for the Global Burden of Disease Study 2016. Lancet Neurol. 2019;18(5):459\u201380. https:\/\/doi.org\/10.1016\/S1474-4422(18)30499-X.","journal-title":"Lancet Neurol"},{"issue":"3\u20134","key":"9808_CR19","doi-asserted-by":"publisher","first-page":"132","DOI":"10.1159\/000360528","volume":"72","author":"CP Kamm","year":"2014","unstructured":"Kamm CP, Uitdehaag BM, Polman CH Multiple sclerosis: current knowledge and future outlook. Eur Neurol. 2014;72(3\u20134):132\u201341. https:\/\/doi.org\/10.1159\/000360528.","journal-title":"Eur Neurol"},{"key":"9808_CR20","doi-asserted-by":"crossref","unstructured":"Wallin MT, Culpepper WJ, Campbell JD, Nelson LM, Langer-gould A, Marrie RA, et al. The prevalence of MS in the United States a population-based estimate using health claims data. 2019;0:1029\u201340.","DOI":"10.1212\/WNL.0000000000007035"},{"issue":"1","key":"9808_CR21","first-page":"22","volume":"24","author":"RR Voskuhl","year":"2019","unstructured":"Voskuhl RR, Sawalha AH, Itoh Y, Program MS, Angeles L, Arbor A. HHS Public Access. 2019;24(1):22\u201331.","journal-title":"HHS Public Access"},{"key":"9808_CR22","doi-asserted-by":"publisher","first-page":"100977","DOI":"10.1016\/j.lanepe.2024.100977","volume":"44","author":"E Portaccio","year":"2024","unstructured":"Portaccio E, Magyari M, Havrdova K, Ruet A, Brochet B, Scalfari A, et al. Series Multiple Sclerosis 2024 Multiple sclerosis\u202f: emerging epidemiological trends and rede fi ning the clinical course. Lancet Reg Heal - Eur [Internet]. 2024;44:100977. https:\/\/doi.org\/10.1016\/j.lanepe.2024.100977.","journal-title":"Lancet Reg Heal - Eur [Internet]"},{"issue":"6","key":"9808_CR23","doi-asserted-by":"publisher","first-page":"829","DOI":"10.1002\/ana.25365","volume":"84","author":"RJ Bevan","year":"2018","unstructured":"Bevan RJ, Evans R, Griffiths L, Watkins LM, Rees MI, Magliozzi R, et al. Meningeal inflammation and cortical demyelination in acute multiple sclerosis. Ann Neurol. 2018;84(6):829\u201342.","journal-title":"Ann Neurol"},{"issue":"8","key":"9808_CR24","doi-asserted-by":"publisher","first-page":"378","DOI":"10.1212\/WNL.0000000000012323","volume":"97","author":"BAC Cree","year":"2021","unstructured":"Cree BAC, Arnold DL, Chataway J, Chitnis T, Fox RJ, Pozo Ramajo A, et al. Secondary Progressive Multiple Sclerosis: New Insights. Neurology. 2021;97(8):378\u201388.","journal-title":"Neurology"},{"key":"9808_CR25","doi-asserted-by":"publisher","unstructured":"Chard DT, Miller DH. What lies beneath grey matter atrophy in multiple sclerosis?. Brain. 2016;139(Pt 1):7\u201310. https:\/\/doi.org\/10.1093\/brain\/awv354.","DOI":"10.1093\/brain\/awv354"},{"key":"9808_CR26","doi-asserted-by":"publisher","unstructured":"Vaughn CB, Benedict RHB, Zivadinov R, Weinstock- B. Epidemiology and treatment of multiple sclerosis in elderly populations. Nat Rev Neurol. 2004. https:\/\/doi.org\/10.1038\/s41582-019-0183-3.","DOI":"10.1038\/s41582-019-0183-3"},{"issue":"9","key":"9808_CR27","doi-asserted-by":"publisher","first-page":"703","DOI":"10.18553\/jmcp.2010.16.9.703","volume":"16","author":"CV Asche","year":"2010","unstructured":"Asche CV, Singer ME, Jhaveri M, Chung H, Pharm BS, Miller AAll-cause health care utilization and costs associated with newly diagnosed multiple sclerosis in the US. J Managed Care Pharm. 2010;16(9):703\u201312. https:\/\/doi.org\/10.18553\/jmcp.2010.16.9.703.","journal-title":"J Managed Care Pharm"},{"issue":"3","key":"9808_CR28","doi-asserted-by":"publisher","first-page":"201","DOI":"10.30476\/IJCBNM.2019.44995","volume":"7","author":"A Dehghani","year":"2019","unstructured":"Dehghani A, Khoramkish M, Shahsavari Isfahani S Challenges in the Daily Living Activities of Patients with Multiple Sclerosis: A Qualitative Content Analysis. Int J Community Based Nurs Midwifery. 2019;7(3):201\u201310. https:\/\/doi.org\/10.30476\/IJCBNM.2019.44995.","journal-title":"Int J Community Based Nurs Midwifery"},{"issue":"18","key":"9808_CR29","doi-asserted-by":"publisher","first-page":"e1810","DOI":"10.1212\/WNL.0000000000200150","volume":"98","author":"B Bebo","year":"2022","unstructured":"Bebo B, Cintina I, LaRocca N, et al The Economic Burden of Multiple Sclerosis in the United States: Estimate of Direct and Indirect Costs. Neurology. 2022;98(18):e1810\u20137. https:\/\/doi.org\/10.1212\/WNL.0000000000200150.","journal-title":"Neurology"},{"issue":"12","key":"9808_CR30","doi-asserted-by":"publisher","first-page":"1354","DOI":"10.18553\/jmcp.2023.23039","volume":"29","author":"M Schauf","year":"2023","unstructured":"Schauf M, Chinthapatla H, Dimri S, Li E, Hartung DM Economic burden of multiple sclerosis in the United States: A systematic literature review. J Manag Care Spec Pharm. 2023;29(12):1354\u201368. https:\/\/doi.org\/10.18553\/jmcp.2023.23039.","journal-title":"J Manag Care Spec Pharm"},{"issue":"8","key":"9808_CR31","doi-asserted-by":"publisher","first-page":"1123","DOI":"10.1177\/1352458517694432","volume":"23","author":"G Kobelt","year":"2017","unstructured":"Kobelt G, Thompson A, Berg J, et al New insights into the burden and costs of multiple sclerosis in Europe. Mult Scler. 2017;23(8):1123\u201336. https:\/\/doi.org\/10.1177\/1352458517694432.","journal-title":"Mult Scler"},{"issue":"13","key":"9808_CR32","doi-asserted-by":"publisher","first-page":"14","DOI":"10.1016\/j.vhri.2017.12.001","volume":"17","author":"IM Mu\u00f1oz-galindo","year":"2018","unstructured":"Mu\u00f1oz-galindo IM, Alexander J, Calder\u00f3n M, Elizabeth N, T\u00e9llez G, Orlando H, et al. Health care cost for multiple sclerosis: the case of a health insurer in Colombia. Value Heal Reg Issues. 2018;17(13):14\u201320. https:\/\/doi.org\/10.1016\/j.vhri.2017.12.001.","journal-title":"Value Heal Reg Issues"},{"issue":"9648","key":"9808_CR33","doi-asserted-by":"publisher","first-page":"1502","DOI":"10.1016\/S0140-6736(08)61620-7","volume":"372","author":"A Compston","year":"2008","unstructured":"Compston A, Coles A. Multiple sclerosis. Lancet. 2008;372(9648):1502\u201317. https:\/\/doi.org\/10.1016\/S0140-6736(08)61620-7.","journal-title":"Lancet"},{"issue":"11","key":"9808_CR34","doi-asserted-by":"publisher","first-page":"647","DOI":"10.1038\/nrneurol.2012.168","volume":"8","author":"H Lassmann","year":"2012","unstructured":"Lassmann H, Van Horssen J, Mahad D. Progressive multiple sclerosis: pathology and pathogenesis. Nat Publ Gr. 2012;8(11):647\u201356. https:\/\/doi.org\/10.1038\/nrneurol.2012.168.","journal-title":"Nat Publ Gr"},{"key":"9808_CR35","doi-asserted-by":"publisher","first-page":"77","DOI":"10.1016\/j.fitote.2016.11.010","volume":"116","author":"S Giacoppo","year":"2017","unstructured":"Giacoppo S, Pollastro F, Grassi G, Bramanti P, Mazzon E. Target regulation of PI3K\/Akt\/mTOR pathway by cannabidiol in treatment of experimental multiple sclerosis. Fitoterapia. 2017;116:77\u201384. https:\/\/doi.org\/10.1016\/j.fitote.2016.11.010.","journal-title":"Fitoterapia"},{"issue":"6","key":"9808_CR36","doi-asserted-by":"publisher","first-page":"1303","DOI":"10.1007\/s12250-021-00450-3","volume":"36","author":"X Wang","year":"2021","unstructured":"Wang X, Wei Z, Jiang Y, Meng Z, Lu M. mTOR signaling: the interface linking cellular metabolism and hepatitis B virus replication. Virol Sin. 2021;36(6):1303\u201314. https:\/\/doi.org\/10.1007\/s12250-021-00450-3.","journal-title":"Virol Sin"},{"key":"9808_CR37","doi-asserted-by":"crossref","unstructured":"Raf R, Erk MEK, Akt PIKP, Chappell WH, Steelman LS, Long JM, et al. Human health abstract: figure 1. 2011;2(3):135\u201364.","DOI":"10.18632\/oncotarget.240"},{"issue":"15\u201316","key":"9808_CR38","doi-asserted-by":"publisher","first-page":"715","DOI":"10.1016\/j.drudis.2011.05.008","volume":"16","author":"F Nicoletti","year":"2011","unstructured":"Nicoletti F, Fagone P, Meroni P, McCubrey J, Bendtzen K. mTOR as a multifunctional therapeutic target in HIV infection. Drug Discov Today. 2011;16(15\u201316):715\u2013721. https:\/\/doi.org\/10.1016\/j.drudis.2011.05.008","journal-title":"Drug Discov Today"},{"key":"9808_CR39","doi-asserted-by":"crossref","unstructured":"Mammana S, Bramanti P, Mazzon E, Cavalli E. Preclinical evaluation of the PI3K \/ Akt \/ mTOR pathway in animal models of multiple sclerosis. 2018;9(9):8263\u201377.","DOI":"10.18632\/oncotarget.23862"},{"key":"9808_CR40","doi-asserted-by":"publisher","DOI":"10.3390\/ijms23158077","author":"AG Vakrakou","year":"2022","unstructured":"Vakrakou AG, Alexaki A, Brinia ME, Anagnostouli M, Stefanis L, Stathopoulos P. The mTOR signaling pathway in multiple sclerosis; from animal models to human data. Int J Mol Sci. 2022. https:\/\/doi.org\/10.3390\/ijms23158077.","journal-title":"Int J Mol Sci"},{"key":"9808_CR41","doi-asserted-by":"crossref","unstructured":"Ransohoff RM, Brown MA. Innate immunity in the central nervous system Find the latest version: Review series Innate immunity in the central nervous system. J Clin Invest. 2012;122(4):1164\u201371. Available from: http:\/\/www.ncbi.nlm.nih.gov\/pubmed\/22466658","DOI":"10.1172\/JCI58644"},{"key":"9808_CR42","doi-asserted-by":"publisher","first-page":"311","DOI":"10.1146\/annurev-med-051113-024537","volume":"66","author":"JJ O'Shea","year":"2015","unstructured":"O'Shea JJ, Schwartz DM, Villarino AV, Gadina M, McInnes IB, Laurence A The JAK-STAT pathway: impact on human disease and therapeutic intervention. Annu Rev Med. 2015;66:311\u201328. https:\/\/doi.org\/10.1146\/annurev-med-051113-024537.","journal-title":"Annu Rev Med"},{"issue":"12","key":"9808_CR43","doi-asserted-by":"publisher","first-page":"1104","DOI":"10.1038\/ni.3031","volume":"15","author":"JT Chang","year":"2014","unstructured":"Chang JT, Wherry EJ, Goldrath AW Molecular regulation of effector and memory T cell differentiation. Nat Immunol. 2014;15(12):1104\u201315. https:\/\/doi.org\/10.1038\/ni.3031.","journal-title":"Nat Immunol"},{"issue":"6","key":"9808_CR44","first-page":"505","volume":"35","author":"Y Liu","year":"2017","unstructured":"Liu Y, Gibson SA, Benveniste EN, Qin H, Biology I, Branch A. HHS Public Access. 2017;35(6):505\u201327.","journal-title":"HHS Public Access"},{"issue":"4","key":"9808_CR45","doi-asserted-by":"publisher","first-page":"406","DOI":"10.1016\/S1474-4422(14)70305-9","volume":"14","author":"B Hemmer","year":"2015","unstructured":"Hemmer B, Kerschensteiner M, Korn T. Role of the innate and adaptive immune responses in the course of multiple sclerosis. Lancet Neurol. 2015;14(4):406\u201319. https:\/\/doi.org\/10.1016\/S1474-4422(14)70305-9.","journal-title":"Lancet Neurol"},{"key":"9808_CR46","doi-asserted-by":"publisher","first-page":"669","DOI":"10.1146\/annurev.immunol.021908.132557","volume":"27","author":"C Auffray","year":"2009","unstructured":"Auffray C, Sieweke MH, Geissmann F. Blood monocytes: development, heterogeneity, and relationship with dendritic cells. Annu Rev Immunol. 2009;27:669\u201392.","journal-title":"Annu Rev Immunol"},{"issue":"6","key":"9808_CR47","doi-asserted-by":"publisher","first-page":"739","DOI":"10.1002\/ana.21800","volume":"66","author":"APD Henderson","year":"2009","unstructured":"Henderson APD, Barnett MH, Parratt JDE, Prineas JW. Multiple sclerosis: distribution of inflammatory cells in newly forming lesions. Ann Neurol. 2009;66(6):739\u201353.","journal-title":"Ann Neurol"},{"issue":"6","key":"9808_CR48","first-page":"1174","volume":"123","author":"A Bitsch","year":"2000","unstructured":"Bitsch A, Schuchardt J, Bunkowski S, Kuhlmann T, Br\u00fcck W. Acute axonal injury in multiple sclerosis. Corr Demy Infla Brain. 2000;123(6):1174\u201383.","journal-title":"Corr Demy Infla Brain"},{"issue":"3","key":"9808_CR49","doi-asserted-by":"publisher","first-page":"886","DOI":"10.1093\/brain\/aws012","volume":"135","author":"MT Fischer","year":"2012","unstructured":"Fischer MT, Sharma R, Lim JL, Haider L, Frischer JM, Drexhage J, et al. NADPH oxidase expression in active multiple sclerosis lesions in relation to oxidative tissue damage and mitochondrial injury. Brain. 2012;135(3):886\u201399.","journal-title":"Brain"},{"issue":"3","key":"9808_CR50","doi-asserted-by":"publisher","first-page":"393","DOI":"10.1084\/jem.192.3.393","volume":"192","author":"H Babbe","year":"2000","unstructured":"Babbe H, Roers A, Waisman A, Lassmann H, Goebels N, Hohlfeld R, et al. Clonal expansions of CD8+ T cells dominate the T cell infiltrate in active multiple sclerosis lesions as shown by micromanipulation and single cell polymerase chain reaction. J Exp Med. 2000;192(3):393\u2013404.","journal-title":"J Exp Med"},{"issue":"3","key":"9808_CR51","doi-asserted-by":"publisher","first-page":"538","DOI":"10.1093\/brain\/awf059","volume":"125","author":"M Jacobsen","year":"2002","unstructured":"Jacobsen M, Cepok S, Quak E, Happel M, Gaber R, Ziegler A, et al. Oligoclonal expansion of memory CD8+ T cells in cerebrospinal fluid from multiple sclerosis patients. Brain. 2002;125(3):538\u201350.","journal-title":"Brain"},{"issue":"1","key":"9808_CR52","doi-asserted-by":"publisher","first-page":"184","DOI":"10.1093\/brain\/aww270","volume":"140","author":"C Laurent","year":"2017","unstructured":"Laurent C, Doroth\u00e9e G, Hunot S, Martin E, Monnet Y, Duchamp M, et al. Hippocampal T cell infiltration promotes neuroinflammation and cognitive decline in a mouse model of tauopathy. Brain. 2017;140(1):184\u2013200.","journal-title":"Brain"},{"key":"9808_CR53","doi-asserted-by":"publisher","unstructured":"Mayne K, White JA, McMurran CE, Rivera FJ, de la Fuente AG Aging and Neurodegenerative Disease: Is the Adaptive Immune System a Friend or Foe? Front Aging Neurosci. 2020;12:572090. https:\/\/doi.org\/10.3389\/fnagi.2020.572090. Published 2020 Sep 23.","DOI":"10.3389\/fnagi.2020.572090"},{"key":"9808_CR54","doi-asserted-by":"publisher","first-page":"1","DOI":"10.3389\/fncel.2021.661838","volume":"15","author":"F Takata","year":"2021","unstructured":"Takata F, Nakagawa S, Matsumoto J, Dohgu S. Blood-brain barrier dysfunction amplifies the development of neuroinflammation: understanding of cellular events in brain microvascular endothelial cells for prevention and treatment of BBB dysfunction. Front Cell Neurosci. 2021;15:1\u201324.","journal-title":"Front Cell Neurosci"},{"key":"9808_CR55","doi-asserted-by":"publisher","first-page":"683","DOI":"10.1146\/annurev.immunol.23.021704.115707","volume":"23","author":"M Sospedra","year":"2005","unstructured":"Sospedra M, Martin R. Immunology of multiple sclerosis. Annu Rev Immunol. 2005;23:683\u2013747.","journal-title":"Annu Rev Immunol"},{"issue":"1","key":"9808_CR56","doi-asserted-by":"publisher","first-page":"24","DOI":"10.1111\/j.1365-2990.2010.01140.x","volume":"37","author":"J Greenwood","year":"2011","unstructured":"Greenwood J, Heasman SJ, Alvarez JI, Prat A, Lyck R, Engelhardt B. Review: leucocyte-endothelial cell crosstalk at the blood-brain barrier: a prerequisite for successful immune cell entry to the brain. Neuropathol Appl Neurobiol. 2011;37(1):24\u201339.","journal-title":"Neuropathol Appl Neurobiol"},{"issue":"1\u20132","key":"9808_CR57","doi-asserted-by":"publisher","first-page":"23","DOI":"10.1016\/j.jns.2011.06.027","volume":"311","author":"J Correale","year":"2011","unstructured":"Correale J, Ysrraelit MC, Gait\u00e1n MI. Vitamin D-mediated immune regulation in multiple sclerosis. J Neurol Sci. 2011;311(1\u20132):23\u201331. https:\/\/doi.org\/10.1016\/j.jns.2011.06.027.","journal-title":"J Neurol Sci"},{"issue":"1","key":"9808_CR58","first-page":"1","volume":"23","author":"NT Ramos","year":"2008","unstructured":"Ramos NT, Bullard CD, Barnum RS. \u57fa\u56e0\u7684\u6539\u53d8NIH Public Access. Bone. 2008;23(1):1\u20137.","journal-title":"Bone"},{"issue":"2","key":"9808_CR59","doi-asserted-by":"publisher","first-page":"e56586","DOI":"10.1371\/journal.pone.0056586","volume":"8","author":"MV Adzemovic","year":"2013","unstructured":"Adzemovic MV, Zeitelhofer M, Eriksson U, Olsson T, Nilsson I Imatinib ameliorates neuroinflammation in a rat model of multiple sclerosis by enhancing blood-brain barrier integrity and by modulating the peripheral immune response. PLoS ONE. 2013;8(2):e56586. https:\/\/doi.org\/10.1371\/journal.pone.0056586.","journal-title":"PLoS ONE"},{"issue":"1","key":"9808_CR60","doi-asserted-by":"publisher","first-page":"95","DOI":"10.1016\/S1474-4422(23)00377-0","volume":"23","author":"B Zierfuss","year":"2024","unstructured":"Zierfuss B, Larochelle C, Prat A. Blood\u2013brain barrier dysfunction in multiple sclerosis: causes, consequences, and potential effects of therapies. Lancet Neurol. 2024;23(1):95\u2013109. https:\/\/doi.org\/10.1016\/S1474-4422(23)00377-0.","journal-title":"Lancet Neurol"},{"key":"9808_CR61","doi-asserted-by":"publisher","first-page":"187","DOI":"10.1007\/978-3-319-45514-3_9","volume-title":"Blood brain barrier inflamm","author":"M Abadier","year":"2017","unstructured":"Abadier M, Lyck R. The blood brain barrier and inflammation. In: Blood brain barrier inflamm. 2017. p. 187\u2013211."},{"issue":"1","key":"9808_CR62","doi-asserted-by":"publisher","first-page":"161","DOI":"10.1002\/eji.202149238","volume":"52","author":"L Marchetti","year":"2022","unstructured":"Marchetti L, Francisco D, Soldati S, Haghayegh Jahromi N, Barcos S, Gruber I, et al. ACKR1 favors transcellular over paracellular T-cell diapedesis across the blood-brain barrier in neuroinflammation in vitro. Eur J Immunol. 2022;52(1):161\u201377.","journal-title":"Eur J Immunol"},{"issue":"6","key":"9808_CR63","first-page":"1","volume":"7","author":"B Broux","year":"2020","unstructured":"Broux B, Zandee S, Gowing E, Charabati M, L\u00e9cuyer MA, Tastet O, et al. Interleukin-26, preferentially produced by TH17 lymphocytes, regulates CNS barrier function. Neurol Neuroimmunol Neuroinflam. 2020;7(6):1\u201312.","journal-title":"Neurol Neuroimmunol Neuroinflam"},{"issue":"2","key":"9808_CR64","doi-asserted-by":"publisher","first-page":"198","DOI":"10.1016\/S1474-4422(18)30451-4","volume":"18","author":"M Filippi","year":"2019","unstructured":"Filippi M, Br\u00fcck W, Chard D, Fazekas F, Geurts JJG, Enzinger C, et al. Association between pathological and MRI findings in multiple sclerosis. Lancet Neurol. 2019;18(2):198\u2013210. https:\/\/doi.org\/10.1016\/S1474-4422(18)30451-4.","journal-title":"Lancet Neurol"},{"key":"9808_CR65","doi-asserted-by":"publisher","first-page":"247","DOI":"10.1146\/annurev.neuro.30.051606.094313","volume":"31","author":"BD Trapp","year":"2008","unstructured":"Trapp BD, Nave KA. Multiple sclerosis: an immune or neurodegenerative disorder? Annu Rev Neurosci. 2008;31:247\u201369.","journal-title":"Annu Rev Neurosci"},{"issue":"4","key":"9808_CR66","doi-asserted-by":"publisher","first-page":"742","DOI":"10.1016\/j.neuron.2018.01.021","volume":"97","author":"C Baecher-Allan","year":"2018","unstructured":"Baecher-Allan C, Kaskow BJ, Weiner HL. Multiple sclerosis: mechanisms and immunotherapy. Neuron. 2018;97(4):742\u201368. https:\/\/doi.org\/10.1016\/j.neuron.2018.01.021.","journal-title":"Neuron"},{"issue":"11","key":"9808_CR67","doi-asserted-by":"publisher","first-page":"2705","DOI":"10.1093\/brain\/awh641","volume":"128","author":"A Kutzelnigg","year":"2005","unstructured":"Kutzelnigg A, Lucchinetti CF, Stadelmann C, Br\u00fcck W, Rauschka H, Bergmann M, et al. Cortical demyelination and diffuse white matter injury in multiple sclerosis. Brain. 2005;128(11):2705\u201312.","journal-title":"Brain"},{"issue":"3","key":"9808_CR68","doi-asserted-by":"publisher","first-page":"641","DOI":"10.1111\/bpa.12813","volume":"30","author":"A Junker","year":"2020","unstructured":"Junker A, Wozniak J, Voigt D, Scheidt U, Antel J, Wegner C, et al. Extensive subpial cortical demyelination is specific to multiple sclerosis. Brain Pathol. 2020;30(3):641\u201352.","journal-title":"Brain Pathol"},{"issue":"6","key":"9808_CR69","doi-asserted-by":"publisher","first-page":"545","DOI":"10.1016\/S1474-4422(14)70049-3","volume":"13","author":"PA Calabresi","year":"2014","unstructured":"Calabresi PA, Radue EW, Goodin D, Jeffery D, Rammohan KW, Reder AT, et al. Safety and efficacy of fingolimod in patients with relapsing-remitting multiple sclerosis (FREEDOMS II): a double-blind, randomised, placebo-controlled, phase 3 trial. Lancet Neurol. 2014;13(6):545\u201356.","journal-title":"Lancet Neurol"},{"key":"9808_CR70","doi-asserted-by":"crossref","unstructured":"Forslin Y, Bergendal, Hashim F, Martola J, Shams S, Wiberg MK, et al. Detection of leukocortical lesions in multiple sclerosis and their association with physical and cognitive impairment: A comparison of conventional and synthetic phase-sensitive inversion recovery mri. Am J Neuroradiol. 2018;39(11):1995\u20132000.","DOI":"10.3174\/ajnr.A5815"},{"issue":"9","key":"9808_CR71","doi-asserted-by":"publisher","first-page":"2755","DOI":"10.1093\/brain\/awr182","volume":"134","author":"OW Howell","year":"2011","unstructured":"Howell OW, Reeves CA, Nicholas R, Carassiti D, Radotra B, Gentleman SM, et al. Meningeal inflammation is widespread and linked to cortical pathology in multiple sclerosis. Brain. 2011;134(9):2755\u201371.","journal-title":"Brain"},{"issue":"5","key":"9808_CR72","doi-asserted-by":"publisher","first-page":"1175","DOI":"10.1093\/brain\/awp070","volume":"132","author":"JM Frischer","year":"2009","unstructured":"Frischer JM, Bramow S, Dal-Bianco A, Lucchinetti CF, Rauschka H, Schmidbauer M, et al. The relation between inflammation and neurodegeneration in multiple sclerosis brains. Brain. 2009;132(5):1175\u201389.","journal-title":"Brain"},{"issue":"1","key":"9808_CR73","first-page":"1","volume":"15","author":"GM Mey","year":"2023","unstructured":"Mey GM, Mahajan KR, DeSilva TM. Neurodegeneration in multiple sclerosis. WIREs Mech Dis. 2023;15(1):1\u201325.","journal-title":"WIREs Mech Dis"},{"key":"9808_CR74","doi-asserted-by":"crossref","unstructured":"Fisniku LK, Chard DT, Jackson JS, Anderson VM, Altmann DR, Miszkiel KA, et al. Gray Matter Atrophy Is Related to Long- Term Disability in Multiple Sclerosis. 2008;247\u201354.","DOI":"10.1002\/ana.21423"},{"issue":"Pt 10","key":"9808_CR75","doi-asserted-by":"publisher","first-page":"2904","DOI":"10.1093\/brain\/aws260","volume":"135","author":"H Lassmann","year":"2012","unstructured":"Lassmann H Cortical lesions in multiple sclerosis: inflammation versus neurodegeneration. Brain. 2012;135(Pt 10):2904\u20135. https:\/\/doi.org\/10.1093\/brain\/aws260.","journal-title":"Brain"},{"issue":"4","key":"9808_CR76","doi-asserted-by":"publisher","first-page":"447","DOI":"10.1016\/j.devcel.2015.01.016","volume":"32","author":"KK Bercury","year":"2015","unstructured":"Bercury KK, Macklin WB Dynamics and mechanisms of CNS myelination. Dev Cell. 2015;32(4):447\u201358. https:\/\/doi.org\/10.1016\/j.devcel.2015.01.016.","journal-title":"Dev Cell"},{"key":"9808_CR77","doi-asserted-by":"publisher","unstructured":"Joshi DC, Zhang CL, Lin TM, et al. Deletion of mitochondrial anchoring protects dysmyelinating shiverer: implications for progressive MS. J Neurosci. 2015;35(13):5293-5306. https:\/\/doi.org\/10.1523\/JNEUROSCI.3859-14.2015.","DOI":"10.1523\/JNEUROSCI.3859-14.2015"},{"key":"9808_CR78","doi-asserted-by":"publisher","unstructured":"Li C, Luo Y, Li S The roles of neural stem cells in myelin regeneration and repair therapy after spinal cord injury. Stem Cell Res Ther. 2024;15(1):204. https:\/\/doi.org\/10.1186\/s13287-024-03825-x. Published 2024 Jul 8.","DOI":"10.1186\/s13287-024-03825-x"},{"issue":"1","key":"9808_CR79","doi-asserted-by":"publisher","first-page":"a020479","DOI":"10.1101\/cshperspect.a020479","volume":"8","author":"M Simons","year":"2015","unstructured":"Simons M, Nave KA, Oligodendrocytes Myelination and Axonal Support. Cold Spring Harb Perspect Biol. 2015;8(1):a020479. https:\/\/doi.org\/10.1101\/cshperspect.a020479. Published 2015 Jun 22.","journal-title":"Cold Spring Harb Perspect Biol"},{"issue":"1","key":"9808_CR80","doi-asserted-by":"publisher","first-page":"167","DOI":"10.1016\/j.immuni.2019.12.004","volume":"52","author":"S Werneburg","year":"2020","unstructured":"Werneburg S, Jung J, Kunjamma RB, et al Targeted Complement Inhibition at Synapses Prevents Microglial Synaptic Engulfment and Synapse Loss in Demyelinating Disease. Immunity. 2020;52(1):167\u2013e1827. https:\/\/doi.org\/10.1016\/j.immuni.2019.12.004.","journal-title":"Immunity"},{"issue":"2","key":"9808_CR81","doi-asserted-by":"publisher","first-page":"91","DOI":"10.1097\/WNF.0b013e3181cbf825","volume":"33","author":"J Chun","year":"2010","unstructured":"Chun J, Hartung HP Mechanism of action of oral fingolimod (FTY720) in multiple sclerosis. Clin Neuropharmacol. 2010;33(2):91\u2013101. https:\/\/doi.org\/10.1097\/WNF.0b013e3181cbf825.","journal-title":"Clin Neuropharmacol"},{"issue":"19","key":"9808_CR82","doi-asserted-by":"publisher","first-page":"3231","DOI":"10.1016\/j.neuron.2024.05.025","volume":"112","author":"T Garton","year":"2024","unstructured":"Garton T, Gadani SP, Gill AJ, Calabresi PA Neurodegeneration and demyelination in multiple sclerosis. Neuron. 2024;112(19):3231\u201351. https:\/\/doi.org\/10.1016\/j.neuron.2024.05.025.","journal-title":"Neuron"},{"issue":"6","key":"9808_CR83","doi-asserted-by":"publisher","first-page":"313","DOI":"10.1016\/s0166-2236(02)02154-9","volume":"25","author":"H Neumann","year":"2002","unstructured":"Neumann H, Medana IM, Bauer J, Lassmann H Cytotoxic T lymphocytes in autoimmune and degenerative CNS diseases. Trends Neurosci. 2002;25(6):313\u20139. https:\/\/doi.org\/10.1016\/s0166-2236(02)02154-9.","journal-title":"Trends Neurosci"},{"issue":"3","key":"9808_CR84","doi-asserted-by":"publisher","first-page":"132","DOI":"10.1016\/j.it.2004.01.007","volume":"25","author":"H Lassmann","year":"2004","unstructured":"Lassmann H, Ransohoff RM The CD4-Th1 model for multiple sclerosis: a critical [correction of crucial] re-appraisal. Trends Immunol. 2004;25(3):132\u20137. https:\/\/doi.org\/10.1016\/j.it.2004.01.007.","journal-title":"Trends Immunol"},{"key":"9808_CR85","doi-asserted-by":"publisher","first-page":"77","DOI":"10.1016\/j.fitote.2016.11.010","volume":"116","author":"S Giacoppo","year":"2017","unstructured":"Giacoppo S, Pollastro F, Grassi G, Bramanti P, Mazzon E. Fitoterapia Target regulation of PI3K \/ Akt \/ mTOR pathway by cannabidiol in treatment of experimental multiple sclerosis. Fitoterapia. 2017;116:77\u201384. https:\/\/doi.org\/10.1016\/j.fitote.2016.11.010.","journal-title":"Fitoterapia"},{"issue":"22","key":"9808_CR86","doi-asserted-by":"publisher","first-page":"3748","DOI":"10.2174\/092986712801661130","volume":"19","author":"DA Altomare","year":"2012","unstructured":"Altomare DA, Khaled AR Homeostasis and the importance for a balance between AKT\/mTOR activity and intracellular signaling. Curr Med Chem. 2012;19(22):3748\u201362. https:\/\/doi.org\/10.2174\/092986712801661130.","journal-title":"Curr Med Chem"},{"issue":"6","key":"9808_CR87","doi-asserted-by":"publisher","first-page":"429","DOI":"10.1016\/j.smim.2012.12.005","volume":"24","author":"X Xu","year":"2012","unstructured":"Xu X, Ye L, Araki K, Ahmed R mTOR, linking metabolism and immunity. Semin Immunol. 2012;24(6):429\u201335. https:\/\/doi.org\/10.1016\/j.smim.2012.12.005.","journal-title":"Semin Immunol"},{"issue":"6","key":"9808_CR88","doi-asserted-by":"publisher","first-page":"3750","DOI":"10.4049\/jimmunol.181.6.3750","volume":"181","author":"RA O'Connor","year":"2008","unstructured":"O'Connor RA, Prendergast CT, Sabatos CA, et al Cutting edge: Th1 cells facilitate the entry of Th17 cells to the central nervous system during experimental autoimmune encephalomyelitis. J Immunol. 2008;181(6):3750\u20134. https:\/\/doi.org\/10.4049\/jimmunol.181.6.3750.","journal-title":"J Immunol"},{"issue":"3\u20134","key":"9808_CR89","doi-asserted-by":"publisher","first-page":"278","DOI":"10.1016\/j.jaut.2011.02.006","volume":"36","author":"S Haylock-jacobs","year":"2011","unstructured":"Haylock-jacobs S, Comerford I, Bunting M, Kara E, Townley S, Klingler-hoffmann M, et al. PI3K d drives the pathogenesis of experimental autoimmune encephalomyelitis by inhibiting effector T cell apoptosis and promoting Th17 differentiation. J Autoimmun. 2011;36(3\u20134):278\u201387. https:\/\/doi.org\/10.1016\/j.jaut.2011.02.006.","journal-title":"J Autoimmun"},{"key":"9808_CR90","doi-asserted-by":"publisher","first-page":"32","DOI":"10.1016\/j.molimm.2019.03.015","volume":"111","author":"H Datler","year":"2019","unstructured":"Datler H, Vogel A, Kerndl M, Baumgartinger C, Musiejovsky L, Makivic N, et al. PI3K activity in dendritic cells exerts paradoxical effects during autoimmune inflammation. Mol Immunol. 2019;111:32\u201342. https:\/\/doi.org\/10.1016\/j.molimm.2019.03.015.","journal-title":"Mol Immunol"},{"issue":"1","key":"9808_CR91","doi-asserted-by":"publisher","first-page":"14709","DOI":"10.1038\/ncomms14709","volume":"8","author":"Y Liu","year":"2017","unstructured":"Liu Y, Marin A, Ejlerskov P, Rasmussen LM, Prinz M, Issazadeh-Navikas S. Neuronal IFN-beta\u2013induced PI3K\/Akt-FoxA1 signalling is essential for generation of FoxA1+ Treg cells. Nat Commun. 2017;8(1):14709.","journal-title":"Nat Commun"},{"issue":"6","key":"9808_CR92","doi-asserted-by":"publisher","first-page":"440","DOI":"10.1038\/nri2548","volume":"9","author":"L Steinman","year":"2009","unstructured":"Steinman L A molecular trio in relapse and remission in multiple sclerosis. Nat Rev Immunol. 2009;9(6):440\u20137. https:\/\/doi.org\/10.1038\/nri2548.","journal-title":"Nat Rev Immunol"},{"issue":"1","key":"9808_CR93","doi-asserted-by":"publisher","first-page":"e24134","DOI":"10.4161\/jkst.24134","volume":"2","author":"CE Egwuagu","year":"2013","unstructured":"Egwuagu CE, Larkin Iii J Therapeutic targeting of STAT pathways in CNS autoimmune diseases. JAKSTAT. 2013;2(1):e24134. https:\/\/doi.org\/10.4161\/jkst.24134.","journal-title":"JAKSTAT"},{"key":"9808_CR94","doi-asserted-by":"publisher","first-page":"1669688","DOI":"10.3389\/fimmu.2025.1669688","volume":"16","author":"R Djidjik","year":"2025","unstructured":"Djidjik R, Lamara Mahammed L, Berkani LM, et al JAK\/STAT in human diseases: a common axis in immunodeficiencies and hematological disorders. Front Immunol. 2025;16:1669688. https:\/\/doi.org\/10.3389\/fimmu.2025.1669688. Published 2025 Dec 8.","journal-title":"Front Immunol"},{"issue":"1","key":"9808_CR95","doi-asserted-by":"publisher","first-page":"402","DOI":"10.1038\/s41392-021-00791-1","volume":"6","author":"X Hu","year":"2021","unstructured":"Hu X, Li J, Fu M, Zhao X, Wang W The JAK\/STAT signaling pathway: from bench to clinic. Signal Transduct Target Ther. 2021;6(1):402. https:\/\/doi.org\/10.1038\/s41392-021-00791-1. Published 2021 Nov 26.","journal-title":"Signal Transduct Target Ther"},{"issue":"9","key":"9808_CR96","doi-asserted-by":"publisher","first-page":"651","DOI":"10.1038\/nrm909","volume":"3","author":"DE Levy Jr.","year":"2002","unstructured":"Levy DE, Darnell JE Jr. Stats: transcriptional control and biological impact. Nat Rev Mol Cell Biol. 2002;3(9):651\u201362. https:\/\/doi.org\/10.1038\/nrm909.","journal-title":"Nat Rev Mol Cell Biol"},{"issue":"1","key":"9808_CR97","doi-asserted-by":"publisher","first-page":"273","DOI":"10.1111\/j.1600-065X.2008.00754.x","volume":"228","author":"K Ghoreschi","year":"2009","unstructured":"Ghoreschi K, Laurence A, O'Shea JJ Janus kinases in immune cell signaling. Immunol Rev. 2009;228(1):273\u201387. https:\/\/doi.org\/10.1111\/j.1600-065X.2008.00754.x.","journal-title":"Immunol Rev"},{"issue":"4","key":"9808_CR98","doi-asserted-by":"publisher","first-page":"231","DOI":"10.1007\/s00005-007-0030-x","volume":"55","author":"JA Ross","year":"2007","unstructured":"Ross JA, Nagy ZS, Cheng H, Stepkowski SM, Kirken RA Regulation of T cell homeostasis by JAKs and STATs. Arch Immunol Ther Exp (Warsz). 2007;55(4):231\u201345. https:\/\/doi.org\/10.1007\/s00005-007-0030-x.","journal-title":"Arch Immunol Ther Exp (Warsz)"},{"issue":"5","key":"9808_CR99","doi-asserted-by":"publisher","first-page":"1062","DOI":"10.1210\/me.2009-0355","volume":"24","author":"LS Argetsinger","year":"2010","unstructured":"Argetsinger LS, Stuckey JA, Robertson SA, et al Tyrosines 868, 966, and 972 in the kinase domain of JAK2 are autophosphorylated and required for maximal JAK2 kinase activity. Mol Endocrinol. 2010;24(5):1062\u201376. https:\/\/doi.org\/10.1210\/me.2009-0355.","journal-title":"Mol Endocrinol"},{"issue":"2","key":"9808_CR100","doi-asserted-by":"publisher","first-page":"285","DOI":"10.1016\/j.ajhg.2010.01.017","volume":"86","author":"E Jakkula","year":"2010","unstructured":"Jakkula E, Lepp\u00e4 V, Sulonen AM, et al Genome-wide association study in a high-risk isolate for multiple sclerosis reveals associated variants in STAT3 gene. Am J Hum Genet. 2010;86(2):285\u201391. https:\/\/doi.org\/10.1016\/j.ajhg.2010.01.017.","journal-title":"Am J Hum Genet"},{"issue":"4","key":"9808_CR101","doi-asserted-by":"publisher","first-page":"403","DOI":"10.1016\/j.cytogfr.2014.07.013","volume":"25","author":"DW Luchtman","year":"2014","unstructured":"Luchtman DW, Ellwardt E, Larochelle C, Zipp F. Cytokine & Growth Factor Reviews IL-17 and related cytokines involved in the pathology and immunotherapy of multiple sclerosis: Current and future developments. Cytokine Growth Factor Rev. 2014;25(4):403\u201313. https:\/\/doi.org\/10.1016\/j.cytogfr.2014.07.013.","journal-title":"Cytokine Growth Factor Rev"},{"key":"9808_CR102","doi-asserted-by":"publisher","first-page":"69","DOI":"10.1016\/j.bbrc.2022.06.081","volume":"620","author":"HI Lee","year":"2022","unstructured":"Lee HI, Kim HJ, Jo S, et al IL-6 activates pathologic Th17 cell via STAT 3 phosphorylation in inflammatory joint of Ankylosing Spondylitis. Biochem Biophys Res Commun. 2022;620:69\u201375. https:\/\/doi.org\/10.1016\/j.bbrc.2022.06.081.","journal-title":"Biochem Biophys Res Commun"},{"issue":"11","key":"9808_CR103","doi-asserted-by":"publisher","first-page":"5139","DOI":"10.4049\/jimmunol.1401680","volume":"194","author":"X Zhang","year":"2015","unstructured":"Zhang X, Tao Y, Chopra M, et al IL-11 Induces Th17 Cell Responses in Patients with Early Relapsing-Remitting Multiple Sclerosis. J Immunol. 2015;194(11):5139\u201349. https:\/\/doi.org\/10.4049\/jimmunol.1401680.","journal-title":"J Immunol"},{"issue":"3","key":"9808_CR104","doi-asserted-by":"publisher","first-page":"1800","DOI":"10.4049\/jimmunol.180.3.1800","volume":"180","author":"F Caprioli","year":"2008","unstructured":"Caprioli F, Sarra M, Caruso R, et al Autocrine regulation of IL-21 production in human T lymphocytes. J Immunol. 2008;180(3):1800\u20137. https:\/\/doi.org\/10.4049\/jimmunol.180.3.1800.","journal-title":"J Immunol"},{"issue":"11","key":"9808_CR105","doi-asserted-by":"publisher","first-page":"1842","DOI":"10.1002\/eji.202149674","volume":"52","author":"L Rani","year":"2022","unstructured":"Rani L, Kumar A, Karhade J, et al IL-3 regulates the differentiation of pathogenic Th17 cells. Eur J Immunol. 2022;52(11):1842\u201358. https:\/\/doi.org\/10.1002\/eji.202149674.","journal-title":"Eur J Immunol"},{"issue":"23","key":"9808_CR106","doi-asserted-by":"publisher","first-page":"1872","DOI":"10.3390\/cells14231872","volume":"14","author":"I Anchesi","year":"2025","unstructured":"Anchesi I, Astorino MF, Raffaele I, et al Psychedelics in Multiple Sclerosis: Mechanisms, Challenges, and Prospects for Neuroimmune Modulation and Repair. Cells. 2025;14(23):1872. https:\/\/doi.org\/10.3390\/cells14231872. Published 2025 Nov 26.","journal-title":"Cells"},{"issue":"8","key":"9808_CR107","doi-asserted-by":"publisher","first-page":"e20212443","DOI":"10.1084\/jem.20212443","volume":"219","author":"C Sie","year":"2022","unstructured":"Sie C, Kant R, Peter C, et al IL-24 intrinsically regulates Th17 cell pathogenicity in mice. J Exp Med. 2022;219(8):e20212443. https:\/\/doi.org\/10.1084\/jem.20212443.","journal-title":"J Exp Med"},{"key":"9808_CR108","doi-asserted-by":"publisher","unstructured":"Lai S, Wu X, Liu Y, Liu B, Wu H, Ma K. Brain , Behavior, & immunity - health interaction between Th17 and central nervous system in multiple sclerosis. Brain Behav Immun-Heal. 2025;43(December 2024):100928. https:\/\/doi.org\/10.1016\/j.bbih.2024.100928.","DOI":"10.1016\/j.bbih.2024.100928"},{"issue":"10","key":"9808_CR109","doi-asserted-by":"publisher","first-page":"5430","DOI":"10.1073\/pnas.1913997117","volume":"117","author":"HC Lu","year":"2020","unstructured":"Lu HC, Kim S, Steelman AJ, et al STAT3 signaling in myeloid cells promotes pathogenic myelin-specific T cell differentiation and autoimmune demyelination. Proc Natl Acad Sci U S A. 2020;117(10):5430\u201341. https:\/\/doi.org\/10.1073\/pnas.1913997117.","journal-title":"Proc Natl Acad Sci U S A"},{"key":"9808_CR110","doi-asserted-by":"publisher","unstructured":"Prado DS, Kutuva AR, Cattley RT et al STAT3 S727 phosphorylation drives pathogenic Th17 differentiation and neuroinflammation in autoimmune disease. J Neuroinflammation. 2025;22(1):246. https:\/\/doi.org\/10.1186\/s12974-025-03591-4. Published 2025 Oct 28.","DOI":"10.1186\/s12974-025-03591-4"},{"issue":"June","key":"9808_CR111","doi-asserted-by":"publisher","first-page":"65","DOI":"10.1016\/j.neuroscience.2024.06.009","volume":"552","author":"Y Xue","year":"2024","unstructured":"Xue Y, Zhang L, Chu L, Song Z, Zhang B, Su X, et al. Neuroscience JAK2 \/ STAT3 pathway inhibition by AG490 ameliorates experimental autoimmune encephalomyelitis via regulation of Th17 cells and autophagy. Neuroscience. 2024;552(June):65\u201375. https:\/\/doi.org\/10.1016\/j.neuroscience.2024.06.009.","journal-title":"Neuroscience"},{"key":"9808_CR112","doi-asserted-by":"publisher","unstructured":"Hu D, Notarbartolo S, Croonenborghs T, Patel B, Cialic R, Yang T hsiang, et al. gene expression in multiple sclerosis. Nat Commun. https:\/\/doi.org\/10.1038\/s41467-017-01571-8.","DOI":"10.1038\/s41467-017-01571-8"},{"issue":"13","key":"9808_CR113","doi-asserted-by":"publisher","first-page":"4463","DOI":"10.18632\/aging.102093","volume":"11","author":"ZH Li","year":"2019","unstructured":"Li ZH, Wang YF, He DD, et al Let-7f-5p suppresses Th17 differentiation via targeting STAT3 in multiple sclerosis. Aging. 2019;11(13):4463\u201377. https:\/\/doi.org\/10.18632\/aging.102093.","journal-title":"Aging"},{"issue":"3","key":"9808_CR114","doi-asserted-by":"publisher","first-page":"1011","DOI":"10.4049\/jimmunol.1004013","volume":"188","author":"L De Conti","year":"2012","unstructured":"Conti L, De Palma R, Rolla S, et al Th17 cells in multiple sclerosis express higher levels of JAK2, which increases their surface expression of IFN-\u03b3R2. J Immunol. 2012;188(3):1011\u20138. https:\/\/doi.org\/10.4049\/jimmunol.1004013.","journal-title":"J Immunol"},{"issue":"1","key":"9808_CR115","doi-asserted-by":"publisher","first-page":"200","DOI":"10.1128\/MCB.24.1.200-216.2004","volume":"24","author":"DC Fingar","year":"2004","unstructured":"Fingar DC, Richardson CJ, Tee AR, Cheatham L, Tsou C, Blenis J. mTOR controls cell cycle progression through its cell growth effectors S6K1 and 4E-BP1\/eukaryotic translation initiation factor 4E. Mol Cell Biol. 2004;24(1):200\u201316. https:\/\/doi.org\/10.1128\/MCB.24.1.200-216.2004.","journal-title":"Mol Cell Biol"},{"issue":"19","key":"9808_CR116","doi-asserted-by":"publisher","first-page":"14071","DOI":"10.1074\/jbc.R109.094003","volume":"285","author":"KG Foster","year":"2010","unstructured":"Foster KG, Fingar DC Mammalian target of rapamycin (mTOR): conducting the cellular signaling symphony. J Biol Chem. 2010;285(19):14071\u20137. https:\/\/doi.org\/10.1074\/jbc.R109.094003.","journal-title":"J Biol Chem"},{"key":"9808_CR117","doi-asserted-by":"publisher","first-page":"3406032","DOI":"10.1155\/2020\/3406032","volume":"2020","author":"P Wang","year":"2020","unstructured":"Wang P, Zhang Q, Tan L, Xu Y, Xie X, Zhao Y The Regulatory Effects of mTOR Complexes in the Differentiation and Function of CD4+ T Cell Subsets. J Immunol Res. 2020;2020:3406032. https:\/\/doi.org\/10.1155\/2020\/3406032. Published 2020 Apr 23.","journal-title":"J Immunol Res"},{"issue":"Pt B","key":"9808_CR118","doi-asserted-by":"publisher","first-page":"501","DOI":"10.1016\/j.expneurol.2016.03.008","volume":"283","author":"JM Gaesser","year":"2016","unstructured":"Gaesser JM, Fyffe-Maricich SL Intracellular signaling pathway regulation of myelination and remyelination in the CNS. Exp Neurol. 2016;283(Pt B):501\u201311. https:\/\/doi.org\/10.1016\/j.expneurol.2016.03.008.","journal-title":"Exp Neurol"},{"issue":"6","key":"9808_CR119","doi-asserted-by":"publisher","first-page":"1383","DOI":"10.1002\/glia.24343","volume":"71","author":"Y Liu","year":"2023","unstructured":"Liu Y, Shen X, Zhang Y, et al Interactions of glial cells with neuronal synapses, from astrocytes to microglia and oligodendrocyte lineage cells. Glia. 2023;71(6):1383\u2013401. https:\/\/doi.org\/10.1002\/glia.24343.","journal-title":"Glia"},{"issue":"26","key":"9808_CR120","doi-asserted-by":"publisher","first-page":"8855","DOI":"10.1523\/JNEUROSCI.0137-12.2012","volume":"32","author":"A Ishii","year":"2012","unstructured":"Ishii A, Fyffe-Maricich SL, Furusho M, Miller RH, Bansal R ERK1\/ERK2 MAPK signaling is required to increase myelin thickness independent of oligodendrocyte differentiation and initiation of myelination. J Neurosci. 2012;32(26):8855\u201364. https:\/\/doi.org\/10.1523\/JNEUROSCI.0137-12.2012.","journal-title":"J Neurosci"},{"issue":"17","key":"9808_CR121","doi-asserted-by":"publisher","first-page":"3050","DOI":"10.1242\/dev.137075","volume":"143","author":"JS Yu","year":"2016","unstructured":"Yu JS, Cui W Proliferation, survival and metabolism: the role of PI3K\/AKT\/mTOR signalling in pluripotency and cell fate determination. Development. 2016;143(17):3050\u201360. https:\/\/doi.org\/10.1242\/dev.137075.","journal-title":"Development"},{"issue":"3","key":"9808_CR122","doi-asserted-by":"publisher","first-page":"301","DOI":"10.1002\/glia.22433","volume":"61","author":"C Dello Russo","year":"2013","unstructured":"Dello Russo C, Lisi L, Feinstein DL, Navarra P. mTOR kinase, a key player in the regulation of glial functions: relevance for the therapy of multiple sclerosis. Glia. 2013;61(3):301\u201311.","journal-title":"Glia"},{"issue":"25","key":"9808_CR123","doi-asserted-by":"publisher","first-page":"8432","DOI":"10.1523\/JNEUROSCI.1105-14.2014","volume":"34","author":"F Lebrun-Julien","year":"2014","unstructured":"Lebrun-Julien F, Bachmann L, Norrm\u00e9n C, et al Balanced mTORC1 activity in oligodendrocytes is required for accurate CNS myelination. J Neurosci. 2014;34(25):8432\u201348. https:\/\/doi.org\/10.1523\/JNEUROSCI.1105-14.2014.","journal-title":"J Neurosci"},{"key":"9808_CR124","doi-asserted-by":"publisher","unstructured":"Astrid M, Jimenez B, Sharma S, Abdolrezaee SK. The integrated stress response in neurodegenerative diseases. Mol Neurodegener. 2025;1\u201320. https:\/\/doi.org\/10.1186\/s13024-025-00811-6.","DOI":"10.1186\/s13024-025-00811-6"},{"issue":"40","key":"9808_CR125","doi-asserted-by":"publisher","first-page":"8321","DOI":"10.1523\/JNEUROSCI.1377-20.2021","volume":"41","author":"MA Jeffries","year":"2021","unstructured":"Jeffries MA, McLane LE, Khandker L, et al mTOR Signaling Regulates Metabolic Function in Oligodendrocyte Precursor Cells and Promotes Efficient Brain Remyelination in the Cuprizone Model. J Neurosci. 2021;41(40):8321\u201337. https:\/\/doi.org\/10.1523\/JNEUROSCI.1377-20.2021.","journal-title":"J Neurosci"},{"issue":"28","key":"9808_CR126","doi-asserted-by":"publisher","first-page":"7174","DOI":"10.1523\/JNEUROSCI.0150-08.2008","volume":"28","author":"AI Flores","year":"2008","unstructured":"Flores AI, Narayanan SP, Morse EN, et al Constitutively active Akt induces enhanced myelination in the CNS. J Neurosci. 2008;28(28):7174\u201383. https:\/\/doi.org\/10.1523\/JNEUROSCI.0150-08.2008.","journal-title":"J Neurosci"},{"key":"9808_CR127","doi-asserted-by":"publisher","first-page":"131","DOI":"10.1016\/j.nbd.2013.04.005","volume":"56","author":"S Kumar","year":"2013","unstructured":"Kumar S, Patel R, Moore S, Crawford DK, Suwanna N, Mangiardi M, et al. Estrogen receptor \u03b2 ligand therapy activates PI3K\/Akt\/mTOR signaling in oligodendrocytes and promotes remyelination in a mouse model of multiple sclerosis. Neurobiol Dis. 2013;56:131\u201344. https:\/\/doi.org\/10.1016\/j.nbd.2013.04.005.","journal-title":"Neurobiol Dis"},{"key":"9808_CR128","doi-asserted-by":"publisher","first-page":"119","DOI":"10.1016\/bs.pbr.2019.03.013","volume":"245","author":"SD Skaper","year":"2019","unstructured":"Skaper SD Oligodendrocyte precursor cells as a therapeutic target for demyelinating diseases. Prog Brain Res. 2019;245:119\u201344. https:\/\/doi.org\/10.1016\/bs.pbr.2019.03.013.","journal-title":"Prog Brain Res"},{"issue":"2","key":"9808_CR129","doi-asserted-by":"publisher","first-page":"271","DOI":"10.1097\/00007890-200101270-00019","volume":"71","author":"AS MacDonald","year":"2001","unstructured":"MacDonald AS, RAPAMUNE Global Study Group. A worldwide, phase III, randomized, controlled, safety and efficacy study of a sirolimus\/cyclosporine regimen for prevention of acute rejection in recipients of primary mismatched renal allografts. Transplantation. 2001;71(2):271\u201380. https:\/\/doi.org\/10.1097\/00007890-200101270-00019.","journal-title":"Transplantation"},{"issue":"11","key":"9808_CR130","doi-asserted-by":"publisher","first-page":"e0188417","DOI":"10.1371\/journal.pone.0188417","volume":"12","author":"MD Grier","year":"2017","unstructured":"Grier MD, West KL, Kelm ND, et al Loss of mTORC2 signaling in oligodendrocyte precursor cells delays myelination. PLoS ONE. 2017;12(11):e0188417. https:\/\/doi.org\/10.1371\/journal.pone.0188417. Published 2017 Nov 21.","journal-title":"PLoS ONE"},{"key":"9808_CR131","doi-asserted-by":"publisher","DOI":"10.1016\/j.celrep.2023.112801","author":"H Huang","year":"2023","unstructured":"Huang H, Jing B, Zhu F, Jiang W, Tang P, Shi L, et al. Disruption of neuronal RHEB signaling impairs oligodendrocyte differentiation and myelination through mTORC1-DLK1 axis. Cell Rep. 2023. https:\/\/doi.org\/10.1016\/j.celrep.2023.112801.","journal-title":"Cell Rep"},{"issue":"2","key":"9808_CR132","doi-asserted-by":"publisher","first-page":"1051","DOI":"10.3892\/etm.2017.4618","volume":"14","author":"Y Wang","year":"2017","unstructured":"Wang Y, Ma Q, Ma X, Zhang Z, Liu N, Wang M Role of mammalian target of rapamycin signaling in autophagy and the neurodegenerative process using a senescence accelerated mouse-prone 8 model. Exp Ther Med. 2017;14(2):1051\u20137. https:\/\/doi.org\/10.3892\/etm.2017.4618.","journal-title":"Exp Ther Med"},{"key":"9808_CR133","doi-asserted-by":"publisher","unstructured":"Fan Y, Chen ZKY, Wang Q. Genetically determined levels of mTOR-dependent circulating proteins and risk of multiple sclerosis. Neurol Ther. 2023;12(3):751\u201362. https:\/\/doi.org\/10.1007\/s40120-023-00455-y.","DOI":"10.1007\/s40120-023-00455-y"},{"key":"9808_CR134","doi-asserted-by":"publisher","unstructured":"Bagherpour B, Salehi M, Jafari R. PT Mult Scler Relat Disord. 2018. https:\/\/doi.org\/10.1016\/j.msard.2018.08.009.","DOI":"10.1016\/j.msard.2018.08.009"},{"issue":"1","key":"9808_CR135","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1007\/s12017-025-08842-4","volume":"27","author":"J Antonio","year":"2025","unstructured":"Antonio J, Cordero F, Aranaz A, Teresa M, Garc\u00eda V, P\u00e9rez A, et al. Leptin and Leptin Signaling in Multiple Sclerosis\u202f: A Narrative Review. NeuroMolecular Med. 2025;27(1):1\u201313. https:\/\/doi.org\/10.1007\/s12017-025-08842-4.","journal-title":"NeuroMolecular Med"},{"issue":"1","key":"9808_CR136","doi-asserted-by":"publisher","first-page":"168","DOI":"10.3390\/ijms27010168","volume":"27","author":"N Abbasi Kasbi","year":"2025","unstructured":"Abbasi Kasbi N, Stopschinski BE, Polyak AG, et al. Leptin as a Potential Modifier of Neuroinflammation: Contrasting Roles in Alzheimer's Disease and Multiple Sclerosis. Int J Mol Sci. 2025;27(1):168. https:\/\/doi.org\/10.3390\/ijms27010168. Published 2025 Dec 23.","journal-title":"Int J Mol Sci"},{"issue":"1","key":"9808_CR137","doi-asserted-by":"publisher","DOI":"10.3390\/biom10010137","volume":"10","author":"A Cianciulli","year":"2020","unstructured":"Cianciulli A, Porro C, Calvello R, Trotta T, Lofrumento DD, Panaro MA. Microglia mediated neuroinflammation: focus on PI3K modulation. Biomolecules. 2020;10(1):137.","journal-title":"Biomolecules"},{"key":"9808_CR138","doi-asserted-by":"publisher","unstructured":"Kooshki L, Nazanin S, Fakhri S, Zachariah S, Echeverria J. Phytomedicine the pivotal role of JAK\/STAT and IRS \/ PI3K signaling pathways in neurodegenerative diseases: mechanistic approaches to polyphenols and alkaloids. Phytomedicine. 2023;112(October 2022):154686. https:\/\/doi.org\/10.1016\/j.phymed.2023.154686.","DOI":"10.1016\/j.phymed.2023.154686"},{"issue":"24","key":"9808_CR139","doi-asserted-by":"publisher","first-page":"25931","DOI":"10.18632\/aging.203781","volume":"13","author":"J Wang","year":"2021","unstructured":"Wang J, Song X, Tan G, et al NAD+ improved experimental autoimmune encephalomyelitis by regulating SIRT1 to inhibit PI3K\/Akt\/mTOR signaling pathway. Aging. 2021;13(24):25931\u201343. https:\/\/doi.org\/10.18632\/aging.203781.","journal-title":"Aging"},{"key":"9808_CR140","doi-asserted-by":"publisher","unstructured":"Sadek MA, Kandil EA, Sayed NS El, Sayed HM, Rabie MA. International immunopharmacology semaglutide, a novel glucagon-like peptide-1 agonist , amends experimental autoimmune encephalomyelitis-induced multiple sclerosis in mice: Involvement of the PI3K\/Akt\/GSK-3 \u03b2 pathway. Int Immunopharmacol. 2023;115(December 2022):109647. https:\/\/doi.org\/10.1016\/j.intimp.2022.109647.","DOI":"10.1016\/j.intimp.2022.109647"},{"issue":"4","key":"9808_CR141","doi-asserted-by":"publisher","first-page":"9322","DOI":"10.1080\/21655979.2022.2052671","volume":"13","author":"K Zheng","year":"2022","unstructured":"Zheng K, Lv B, Wu L, Wang C, Xu H, Li X, et al. Protecting effect of emodin in experimental autoimmune encephalomyelitis mice by inhibiting microglia activation and inflammation via Myd88 \/ PI3K \/ Akt \/ NF-\u03baB signalling pathway. Bioengineered. 2022;13(4):9322\u201344. https:\/\/doi.org\/10.1080\/21655979.2022.2052671.","journal-title":"Bioengineered"},{"issue":"4","key":"9808_CR142","doi-asserted-by":"publisher","first-page":"e142376","DOI":"10.1172\/jci.insight.142376","volume":"6","author":"SI Aqel","year":"2021","unstructured":"Aqel SI, Yang X, Kraus EE, et al A STAT3 inhibitor ameliorates CNS autoimmunity by restoring Teff:Treg balance. JCI Insight. 2021;6(4):e142376. Published 2021 Feb 22. https:\/\/doi.org\/10.1172\/jci.insight.142376.","journal-title":"JCI Insight"},{"issue":"7","key":"9808_CR143","doi-asserted-by":"publisher","first-page":"925","DOI":"10.3390\/pharmaceutics13070925","volume":"13","author":"K Alhazzani","year":"2021","unstructured":"Alhazzani K, Ahmad SF, Al-Harbi NO, et al Pharmacological Inhibition of STAT3 by Stattic Ameliorates Clinical Symptoms and Reduces Autoinflammation in Myeloid, Lymphoid, and Neuronal Tissue Compartments in Relapsing-Remitting Model of Experimental Autoimmune Encephalomyelitis in SJL\/J Mice. Pharmaceutics. 2021;13(7):925. https:\/\/doi.org\/10.3390\/pharmaceutics13070925. Published 2021 Jun 22.","journal-title":"Pharmaceutics"},{"issue":"January","key":"9808_CR144","doi-asserted-by":"publisher","first-page":"104658","DOI":"10.1016\/j.msard.2023.104658","volume":"73","author":"SF Ahmad","year":"2023","unstructured":"Ahmad SF, Ansari MA, Nadeem A, Bakheet SA, Al-mazroua HA, Alomar HA, et al. S3I\u2013201, a selective stat3 inhibitor, ameliorates clinical symptoms in a mouse model of experimental autoimmune encephalomyelitis through the regulation of multiple intracellular signalling in Th1, Th17, and treg cells. Mult Scler Relat Disord. 2023;73(January):104658. https:\/\/doi.org\/10.1016\/j.msard.2023.104658.","journal-title":"Mult Scler Relat Disord"},{"key":"9808_CR145","doi-asserted-by":"publisher","unstructured":"Chen JY, Tian XY, Wei SS, Xu W, Pan RR, Chen LL, et al. Phytomedicine magnolol as STAT3 inhibitor for treating multiple sclerosis by restricting. Phytomedicine. 2023;117(November 2022):154917. https:\/\/doi.org\/10.1016\/j.phymed.2023.154917.","DOI":"10.1016\/j.phymed.2023.154917"},{"key":"9808_CR146","doi-asserted-by":"crossref","unstructured":"Li X, Zhao L, Han J juan, Zhang F, Liu S, Zhu L, et al. Carnosol modulates Th17 cell differentiation and microglial switch in experimental autoimmune encephalomyelitis. 2018;9(August):1\u201312.","DOI":"10.3389\/fimmu.2018.01807"},{"issue":"1","key":"9808_CR147","doi-asserted-by":"publisher","first-page":"e29742","DOI":"10.1371\/journal.pone.0029742","volume":"7","author":"CR Yu","year":"2012","unstructured":"Yu CR, Lee YS, Mahdi RM, Surendran N, Egwuagu CE Therapeutic targeting of STAT3 (signal transducers and activators of transcription 3) pathway inhibits experimental autoimmune uveitis. PLoS ONE. 2012;7(1):e29742. https:\/\/doi.org\/10.1371\/journal.pone.0029742.","journal-title":"PLoS ONE"},{"key":"9808_CR148","unstructured":"Eae E, Mbanefo EC, Seifert A, Yadav MK, Yu C rong, Nagarajan V, et al. A camelid-derived STAT-specific nanobody inhibits. 2024."},{"key":"9808_CR149","doi-asserted-by":"publisher","unstructured":"Sanadgol N, Barati M, Houshmand F, Hassani S, Clarner T. Metformin accelerates myelin recovery and ameliorates behavioral deficits in the animal model of multiple sclerosis via adjustment of AMPK\/Nrf2\/mTOR signaling and maintenance of endogenous oligodendrogenesis during brain self \u2011 repairing period. Pharmacol Rep. 2019;(0123456789). https:\/\/doi.org\/10.1007\/s43440-019-00019-8.","DOI":"10.1007\/s43440-019-00019-8"},{"key":"9808_CR150","doi-asserted-by":"publisher","first-page":"590884","DOI":"10.3389\/fneur.2020.590884","volume":"11","author":"XL Li","year":"2020","unstructured":"Li XL, Zhang B, Liu W, et al Rapamycin Alleviates the Symptoms of Multiple Sclerosis in Experimental Autoimmune Encephalomyelitis (EAE) Through Mediating the TAM-TLRs-SOCS Pathway. Front Neurol. 2020;11:590884. . Published 2020 Nov 27. https:\/\/doi.org\/10.3389\/fneur.2020.590884.","journal-title":"Front Neurol"},{"key":"9808_CR151","doi-asserted-by":"publisher","first-page":"27","DOI":"10.1016\/j.bbrc.2021.08.010","volume":"573","author":"M He","year":"2021","unstructured":"He M, Wu DM, Zhao YY, et al AZD8055 ameliorates experimental autoimmune encephalomyelitis via the mTOR\/ROS\/NLRP3 pathway. Biochem Biophys Res Commun. 2021;573:27\u201334. https:\/\/doi.org\/10.1016\/j.bbrc.2021.08.010.","journal-title":"Biochem Biophys Res Commun"},{"key":"9808_CR152","doi-asserted-by":"publisher","DOI":"10.1016\/j.lfs.2020.117747","volume":"253","author":"L Xu","year":"2020","unstructured":"Xu L, Zhang C, He D, Jiang N, Bai Y, Xin Y. Rapamycin and MCC950 modi fi ed gut microbiota in experimental autoimmune encephalomyelitis mouse by brain gut axis. Life Sci. 2020;253:117747. https:\/\/doi.org\/10.1016\/j.lfs.2020.117747.","journal-title":"Life Sci"},{"issue":"4","key":"9808_CR153","doi-asserted-by":"publisher","first-page":"5160","DOI":"10.1002\/jcb.27792","volume":"120","author":"L Xu","year":"2019","unstructured":"Xu L, Zhang C, Jiang N, He D, Bai Y, Xin Y Rapamycin combined with MCC950 to treat multiple sclerosis in experimental autoimmune encephalomyelitis. J Cell Biochem. 2019;120(4):5160\u20138. https:\/\/doi.org\/10.1002\/jcb.27792.","journal-title":"J Cell Biochem"},{"key":"9808_CR154","doi-asserted-by":"publisher","DOI":"10.1007\/s11064-017-2296-7","author":"H Hou","year":"2017","unstructured":"Hou H, Miao J, Cao R, Han M, Sun Y, Liu X. Rapamycin ameliorates experimental autoimmune encephalomyelitis by suppressing the mTOR-STAT3 pathway. Neurochem Res. 2017. https:\/\/doi.org\/10.1007\/s11064-017-2296-7.","journal-title":"Neurochem Res"},{"issue":"2","key":"9808_CR155","doi-asserted-by":"publisher","first-page":"135","DOI":"10.1016\/j.jaut.2009.06.003","volume":"33","author":"M Donia","year":"2009","unstructured":"Donia M, Mangano K, Amoroso A, Clorinda M, Imbesi R, Castrogiovanni P, et al. Treatment with rapamycin ameliorates clinical and histological signs of protracted relapsing experimental allergic encephalomyelitis in Dark Agouti rats and induces expansion of peripheral CD4 \u00fe CD25 \u00fe Foxp3 \u00fe regulatory T cells. J Autoimmun [Internet]. 2009;33(2):135\u201340. https:\/\/doi.org\/10.1016\/j.jaut.2009.06.003.","journal-title":"J Autoimmun [Internet]"},{"key":"9808_CR156","doi-asserted-by":"publisher","unstructured":"LaMothe RA, Kolte PN, Vo T et al Tolerogenic Nanoparticles Induce Antigen-Specific Regulatory T Cells and Provide Therapeutic Efficacy and Transferrable Tolerance against Experimental Autoimmune Encephalomyelitis. Front Immunol. 2018;9:281. https:\/\/doi.org\/10.3389\/fimmu.2018.00281.\u00a0Published 2018 Mar 2.","DOI":"10.3389\/fimmu.2018.00281"},{"issue":"1\u20132","key":"9808_CR157","doi-asserted-by":"publisher","first-page":"52","DOI":"10.1016\/j.jneuroim.2010.01.001","volume":"220","author":"M Esposito","year":"2010","unstructured":"Esposito M, Ruffini F, Bellone M, et al Rapamycin inhibits relapsing experimental autoimmune encephalomyelitis by both effector and regulatory T cells modulation. J Neuroimmunol. 2010;220(1\u20132):52\u201363. https:\/\/doi.org\/10.1016\/j.jneuroim.2010.01.001.","journal-title":"J Neuroimmunol"},{"key":"9808_CR158","doi-asserted-by":"publisher","unstructured":"Betul F, Vuslat O, Recai Y, Ece T, Erdem A, Gunnur T. Expression of Akt1 and p \u2011 Akt1 in peripheral T cell subsets of multiple sclerosis patients. Acta Neurol Belg. 2020;(0123456789). https:\/\/doi.org\/10.1007\/s13760-020-01518-9.","DOI":"10.1007\/s13760-020-01518-9"},{"key":"9808_CR159","doi-asserted-by":"publisher","unstructured":"Hosseini A, Babaloo Z, Gharibi T, Shomali N, Marofi F, Hashemi V, et al. Epigenetic mechanisms shape the underlining expression regulatory mechanisms of the STAT3 in multiple sclerosis disease. BMC Res Notes. 2020;1\u20136. https:\/\/doi.org\/10.1186\/s13104-020-05427-1.","DOI":"10.1186\/s13104-020-05427-1"},{"issue":"2","key":"9808_CR160","doi-asserted-by":"publisher","first-page":"141","DOI":"10.22034\/iji.2016.16665","volume":"13","author":"M Salehi","year":"2016","unstructured":"Salehi M, Bagherpour B, Shayghannejad V, Mohebi F, Jafari R. Th1, Th2 and Th17 Cytokine Profile in Patients with Multiple Sclerosis Following Treatment with Rapamycin. Iran J Immunol. 2016;13(2):141\u20137. https:\/\/doi.org\/10.22034\/iji.2016.16665.","journal-title":"Iran J Immunol"},{"issue":"5","key":"9808_CR161","doi-asserted-by":"publisher","first-page":"667","DOI":"10.1002\/ana.21958","volume":"67","author":"B van den Moraal","year":"2010","unstructured":"Moraal B, van den Elskamp IJ, Knol DL, et al. Long-interval T2-weighted subtraction magnetic resonance imaging: a powerful new outcome measure in multiple sclerosis trials. Ann Neurol. 2010;67(5):667\u201375. https:\/\/doi.org\/10.1002\/ana.21958.","journal-title":"Ann Neurol"},{"issue":"5","key":"9808_CR162","doi-asserted-by":"publisher","first-page":"520","DOI":"10.1001\/jamaneurol.2015.4807","volume":"73","author":"L Negrotto","year":"2016","unstructured":"Negrotto L, Farez MF, Correale J. Immunologic Effects of Metformin and Pioglitazone Treatment on Metabolic Syndrome and Multiple Sclerosis. JAMA Neurol. 2016;73(5):520\u20138. https:\/\/doi.org\/10.1001\/jamaneurol.2015.4807.","journal-title":"JAMA Neurol"},{"issue":"4","key":"9808_CR163","doi-asserted-by":"publisher","first-page":"605","DOI":"10.1016\/j.cell.2017.07.029","volume":"170","author":"DA Fruman","year":"2017","unstructured":"Fruman DA, Chiu H, Hopkins BD, Bagrodia S, Cantley LC, Abraham RT. Review The PI3K Pathway in Human Disease. Cell [Internet]. 2017;170(4):605\u201335. https:\/\/doi.org\/10.1016\/j.cell.2017.07.029.","journal-title":"Cell [Internet]"},{"issue":"1","key":"9808_CR164","doi-asserted-by":"publisher","first-page":"485","DOI":"10.1146\/annurev.immunol.021908.132710","volume":"27","author":"T Korn","year":"2009","unstructured":"Korn T, Bettelli E, Oukka M, Kuchroo VK. IL-17 and Th17 cells. Annu Rev Immunol. 2009;27(1):485\u2013517.","journal-title":"Annu Rev Immunol"},{"issue":"5","key":"9808_CR165","doi-asserted-by":"publisher","first-page":"448","DOI":"10.1038\/ni.3153","volume":"16","author":"CA Hunter","year":"2015","unstructured":"Hunter CA, Jones SA. IL-6 as a keystone cytokine in health and disease. Nat Immunol. 2015;16(5):448\u201357.","journal-title":"Nat Immunol"},{"issue":"13","key":"9808_CR166","doi-asserted-by":"publisher","first-page":"9358","DOI":"10.1074\/jbc.C600321200","volume":"282","author":"XO Yang","year":"2007","unstructured":"Yang XO, Panopoulos AD, Nurieva R, Chang SH, Wang D, Watowich SS, et al. STAT3 regulates cytokine-mediated generation of inflammatory helper T cells. J Biol Chem. 2007;282(13):9358\u201363.","journal-title":"J Biol Chem"},{"issue":"4","key":"9808_CR167","doi-asserted-by":"publisher","first-page":"295","DOI":"10.1038\/ni.2005","volume":"12","author":"GM Delgoffe","year":"2011","unstructured":"Delgoffe GM, Pollizzi KN, Waickman AT, Heikamp E, Meyers DJ, Horton MR, et al. The mammalian target of rapamycin (mTOR) regulates T helper cell differentiation through the selective activation of mTORC1 and mTORC2 signaling. Nat Immunol. 2011;12(4):295.","journal-title":"Nat Immunol"},{"issue":"13","key":"9808_CR168","doi-asserted-by":"publisher","first-page":"5004","DOI":"10.1073\/pnas.1117218109","volume":"109","author":"H Qin","year":"2012","unstructured":"Qin H, Yeh WI, De Sarno P, Holdbrooks AT, Liu Y, Muldowney MT, et al. Signal transducer and activator of transcription-3\/suppressor of cytokine signaling-3 (STAT3\/SOCS3) axis in myeloid cells regulates neuroinflammation. Proc Natl Acad Sci U S A. 2012;109(13):5004\u20139.","journal-title":"Proc Natl Acad Sci U S A"},{"key":"9808_CR169","doi-asserted-by":"crossref","unstructured":"Pinheiro MA, Kooij G, Mizee MR, Kamermans A, Enzmann G, Lyck R, Schwaninger M, Engelhardt B, de Vries HE. Immune cell trafficking across the barriers of the central nervous system in multiple sclerosis and stroke. Biochim et Biophys Acta (BBA)-Mol Basis Dis. 2016;1862(3):461\u201371.","DOI":"10.1016\/j.bbadis.2015.10.018"},{"issue":"19","key":"9808_CR170","doi-asserted-by":"publisher","first-page":"6367","DOI":"10.1523\/JNEUROSCI.0234-09.2009","volume":"29","author":"WA Tyler","year":"2009","unstructured":"Tyler WA, Gangoli N, Gokina P, Kim HA, Covey M, Levison SW, et al. Activation of the mammalian target of rapamycin (mTOR) is essential for oligodendrocyte differentiation. J Neurosci. 2009;29(19):6367\u201378.","journal-title":"J Neurosci"},{"key":"9808_CR171","doi-asserted-by":"publisher","first-page":"182","DOI":"10.1016\/j.ejphar.2015.03.042","volume":"759","author":"C Procaccini","year":"2015","unstructured":"Procaccini C, De Rosa V, Pucino V, Formisano L, Matarese G. Animal models of multiple sclerosis. Eur J Pharmacol. 2015;759:182\u201391.","journal-title":"Eur J Pharmacol"},{"issue":"2","key":"9808_CR172","doi-asserted-by":"publisher","first-page":"406","DOI":"10.1016\/j.immuni.2016.01.028","volume":"44","author":"C Procaccini","year":"2016","unstructured":"Procaccini C, Carbone F, Di Silvestre D, Brambilla F, De Rosa V, Galgani M, et al. The proteomic landscape of human ex vivo regulatory and conventional T cells reveals specific metabolic requirements. Immunity. 2016;44(2):406\u201321.","journal-title":"Immunity"},{"key":"9808_CR173","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.cytogfr.2016.05.001","volume":"31","author":"EJ Hillmer","year":"2016","unstructured":"Hillmer EJ, Zhang H, Li HS, Watowich SS. STAT3 signaling in immunity. Cytokine Growth Factor Rev. 2016;31:1\u20135.","journal-title":"Cytokine Growth Factor Rev"},{"issue":"6","key":"9808_CR174","doi-asserted-by":"publisher","first-page":"960","DOI":"10.1016\/j.cell.2017.02.004","volume":"168","author":"RA Saxton","year":"2017","unstructured":"Saxton RA, Sabatini DM. mTOR signaling in growth, metabolism, and disease. Cell. 2017;168(6):960\u201376.","journal-title":"Cell"},{"issue":"11","key":"9808_CR175","doi-asserted-by":"publisher","first-page":"703","DOI":"10.1038\/nri.2017.75","volume":"17","author":"L Lu","year":"2017","unstructured":"Lu L, Barbi J, Pan F. The regulation of immune tolerance by FOXP3. Nat Rev Immunol. 2017;17(11):703\u201317.","journal-title":"Nat Rev Immunol"},{"issue":"1\u20132","key":"9808_CR176","doi-asserted-by":"publisher","first-page":"106","DOI":"10.1016\/j.jneuroim.2013.06.007","volume":"262","author":"A Jamshidian","year":"2013","unstructured":"Jamshidian A, Shaygannejad V, Pourazar A, Zarkesh-Esfahani SH, Gharagozloo M. Biased Treg\/Th17 balance away from regulatory toward inflammatory phenotype in relapsed multiple sclerosis and its correlation with severity of symptoms. J Neuroimmunol. 2013;262(1\u20132):106\u201312.","journal-title":"J Neuroimmunol"},{"issue":"1","key":"9808_CR177","doi-asserted-by":"publisher","DOI":"10.1038\/s41389-020-00292-w","volume":"10","author":"J Wang","year":"2021","unstructured":"Wang J, Lv X, Guo X, Dong Y, Peng P, Huang F, et al. Feedback activation of STAT3 limits the response to PI3K\/AKT\/mTOR inhibitors in PTEN-deficient cancer cells. Oncogenesis. 2021;10(1):8.","journal-title":"Oncogenesis"},{"issue":"1","key":"9808_CR178","doi-asserted-by":"publisher","DOI":"10.1016\/j.tjpad.2024.100013","volume":"12","author":"Z Valiukas","year":"2025","unstructured":"Valiukas Z, Tangalakis K, Apostolopoulos V, Feehan J. Microglial activation states and their implications for Alzheimer\u2019s disease. J Prev Alzheimers Dis. 2025;12(1):100013.","journal-title":"J Prev Alzheimers Dis"},{"issue":"21","key":"9808_CR179","doi-asserted-by":"publisher","DOI":"10.3390\/ijms252111638","volume":"25","author":"B Wright","year":"2024","unstructured":"Wright B, King S, Suphioglu C. The importance of phosphoinositide 3-kinase in neuroinflammation. Int J Mol Sci. 2024;25(21):11638.","journal-title":"Int J Mol Sci"},{"issue":"8","key":"9808_CR180","doi-asserted-by":"publisher","first-page":"687","DOI":"10.1016\/j.arcmed.2014.11.013","volume":"45","author":"GG Ortiz","year":"2014","unstructured":"Ortiz GG, Pacheco-Mois\u00e9s FP, Mac\u00edas-Islas M\u00c1, Flores-Alvarado LJ, Mireles-Ram\u00edrez MA, Gonz\u00e1lez-Renovato ED, et al. Role of the blood\u2013brain barrier in multiple sclerosis. Arch Med Res. 2014;45(8):687\u201397.","journal-title":"Arch Med Res"},{"issue":"2","key":"9808_CR181","doi-asserted-by":"publisher","first-page":"137","DOI":"10.1038\/ni1551","volume":"9","author":"R Cayrol","year":"2008","unstructured":"Cayrol R, Wosik K, Berard JL, Dodelet-Devillers A, Ifergan I, Kebir H, et al. Activated leukocyte cell adhesion molecule promotes leukocyte trafficking into the central nervous system. Nat Immunol. 2008;9(2):137\u201345.","journal-title":"Nat Immunol"},{"issue":"Pt 5","key":"9808_CR182","doi-asserted-by":"publisher","first-page":"936","DOI":"10.1042\/BST0340936","volume":"34","author":"GE Hardingham","year":"2006","unstructured":"Hardingham GE. Pro-survival signalling from the NMDA receptor. Biochem Soc Trans. 2006;34(Pt 5):936\u20138. https:\/\/doi.org\/10.1042\/BST0340936.","journal-title":"Biochem Soc Trans"},{"issue":"28","key":"9808_CR183","doi-asserted-by":"publisher","first-page":"7231","DOI":"10.1523\/JNEUROSCI.1709-08.2008","volume":"28","author":"JE Herrmann","year":"2008","unstructured":"Herrmann JE, Imura T, Song B, Qi J, Ao Y, Nguyen TK, et al. STAT3 is a critical regulator of astrogliosis and scar formation after spinal cord injury. J Neurosci. 2008;28(28):7231\u201343.","journal-title":"J Neurosci"},{"issue":"8","key":"9808_CR184","doi-asserted-by":"publisher","first-page":"1152","DOI":"10.3390\/ph18081152","volume":"18","author":"T Bobkova","year":"2025","unstructured":"Bobkova T, Bobkov A, Li Y. Pharmacological Inhibition of the PI3K\/AKT\/mTOR Pathway in Rheumatoid Arthritis Synoviocytes: A Systematic Review and Meta-Analysis (Preclinical). Pharmaceuticals (Basel). 2025;18(8):1152. https:\/\/doi.org\/10.3390\/ph18081152.\u00a0Published 2025 Aug 2.","journal-title":"Pharmaceuticals (Basel)"},{"issue":"1","key":"9808_CR185","doi-asserted-by":"publisher","first-page":"130","DOI":"10.1186\/s13020-025-01176-0","volume":"20","author":"W Yang","year":"2025","unstructured":"Yang W, Lu J, Luo P, et al. An exhaustive examination of the research progress in identifying potential JAK inhibitors from natural products: a comprehensive overview. Chin Med. 2025;20(1):130. https:\/\/doi.org\/10.1186\/s13020-025-01176-0.\u00a0Published 2025 Aug 21.","journal-title":"Chin Med"},{"key":"9808_CR186","doi-asserted-by":"publisher","first-page":"1008116","DOI":"10.37349\/eds.2025.1008116","volume":"3","author":"H De Aliashrafzadeh","year":"2025","unstructured":"Aliashrafzadeh H, Liu D, De Alba S, et al. Experimental and clinical tests of FDA-approved kinase inhibitors for the treatment of neurological disorders (update 2024). Explor Drug Sci. 2025;3:1008116. https:\/\/doi.org\/10.37349\/eds.2025.1008116.","journal-title":"Explor Drug Sci"},{"issue":"2","key":"9808_CR187","doi-asserted-by":"publisher","first-page":"114769","DOI":"10.1016\/j.yexcr.2025.114769","volume":"452","author":"L Naserpour","year":"2025","unstructured":"Naserpour L, Zare S, Khoshandam M. Molecular mechanism and the main signaling pathways in the development and progression of multiple sclerosis. Exp Cell Res. 2025;452(2):114769. https:\/\/doi.org\/10.1016\/j.yexcr.2025.114769.","journal-title":"Exp Cell Res"}],"container-title":["Immunologic Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12026-026-09808-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s12026-026-09808-9","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12026-026-09808-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,7,17]],"date-time":"2026-07-17T08:02:25Z","timestamp":1784275345000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s12026-026-09808-9"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,7,17]]},"references-count":187,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["9808"],"URL":"https:\/\/doi.org\/10.1007\/s12026-026-09808-9","relation":{},"ISSN":["1559-0755"],"issn-type":[{"value":"1559-0755","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,7,17]]},"assertion":[{"value":"26 March 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"9 July 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"17 July 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Not applicable.","order":1,"name":"Ethics","label":"Ethics approval","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Authors approve for submitting the publication.","order":2,"name":"Ethics","label":"Consent to publish","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":3,"name":"Ethics","label":"Consent to participate","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no competing interests.","order":4,"name":"Ethics","label":"Competing interests","group":{"name":"EthicsHeading","label":"Declarations"}}],"article-number":"72"}}